


Understanding cooperative effects in PROTAC-Mediated Ternary Complexes for Protein Degradation



Computational
Molecular
Design
Lab





UNIVERSITAT DE
BARCELONA

Jordi Juarez-Jimenez, PhD


16th RES User Conference

14th September 2022

PROTAC: bifunctional molecules for Targeted Protein Degradation



There are several possibilities to innovate in the design of protein degraders...



Therapeutical advantages of protein degradation over protein modulation



There are **great expectations** on the number and type of targets that can be engaged.




Opportunity to **repurpose compound libraries** with limited affinity or with sub-optimal phenotypic effects.



Early development stage grants great scope for securing **novel intellectual property**.

... but protein degradation remains a mostly empirical field



IN THE PIPELINE

Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of *Science Translational Medicine*. All content is Derek's own, and he does not in any way speak for his employer.



By Derek Lowe
Twitter Email RSS


CHEMICAL BIOLOGY

Linked-Up Molecules Through the Years


By Derek Lowe | 14 November, 2019

“TPD remains a rather. . .*empirical*. . .field for now, which in practice means that you’d better try this and try that and try that other thing over there, what the heck. It would make everyone feel better if that weren’t the case, and everyone would be far more efficient steely-eyed protein degradation masters sitting in mission control and pointing out targets, but that is a vision for the future.”


How CADD can contribute to the future of TPD




Identification new TPD efectors
and new degradable targets.



Understanding the
physicochemical phenomena
underlying TPD.




Generation of predictive and
reliable models of cooperative
effects and degradation.




Development of integrated
computational-experimental
workflows.


Design of PROTACs requires considering three-body complexes





Two-body complex





Three-body complex



Cooperativity: when the total is not the sum of its parts



Cooperativity: when the total is not the sum of its parts



If no cooperativity:

$$\Delta G1 = \Delta G4$$





$$\Delta G2 = \Delta G3$$

If cooperativity:

$$\Delta G1 \neq \Delta G4$$

$$\Delta G2 \neq \Delta G3$$

The Cereblon-Lenalidomide-CK1 α interaction



If no cooperativity:

$$\Delta G1 = \Delta G4$$


$$\Delta G2 = \Delta G3$$

If cooperativity:





$$\Delta G1 \neq \Delta G4$$

$$\Delta G2 \neq \Delta G3$$

Methodological approach



Steered Molecular Dynamics





$$\langle W_{A \rightarrow B} \rangle = W_{QS} + W_{Dis} > \Delta G_{A \rightarrow B}$$

Jarzynski's equality:

$$e^{-\Delta G/k_B T} = \langle e^{-W_i/k_B T} \rangle$$

$$\Delta G_{A \rightarrow B} = -k_B T \ln \sum_{i=1}^N \frac{e^{-W_i/k_B T}}{N}$$


HPC servers are essential for the implementation of the approach



Required wallclock time (Local resources):

ca. 6h x SMD
x 3 H-bonds
x 100 SMD
x 6 systems

ca. 450 days!






RED ESPAÑOLA DE
SUPERCOMPUTACIÓN




Real wallclock time (MareNostrum4 Power9):

ca. 10 days


Lenalidomide strengthens the three key H-bonds







N39-W400







T38-H357



I37-N351




H-bonds in the ternary complex are highly shielded from incoming water molecules





N39-W400

T38-H357

I37-N351




CRBN-Len-^{N39G}CK1 α has weaker H-bonds and reduced hydrophobic shielding



N39-W400

T38-H357



I37-N351






N39-W400

T38-H357



I37-N351




^{135}G CK1 α and ^{137}E CK1 α display less dependence between H-bond strength and shielding



CRBN-Len-^{G40N}CK1 α has the weakest set of H-bonds but the highest hydrophobic shielding




N39-W400
T38-H357
I37-N351





N39-W400

T38-H357


I37-N351



Mutations in CK1 affect the strength of H-bonds even in the presence of lenalidomide











Breakage of the three H-bonds shows little interdependence





N39-W400

T38-H357



I37-N351




The additive PMF correlates with the affinity of the ternary complex




PMF_{dis} H-bond (kcal/mol)




Conclusions




Understanding chemical cooperativity will help in the rational design of PROTACs.




New approaches and workflows will be required for CADD to have an impact in the design of PROTACS.





TPD based on PROTACs are an emerging and promising technology for the development of new therapeutics.



Conclusions




The affinity of Lenalidomide mediated CRBN-CK1 α complexes relies on the strength of three key H-bond interactions.





Establishing the strength of key H-bonds in protein-protein interactions can rank the stability of ternary complexes involving similar partners.

CRBN-CK1 α provides proof of concept for an easy-to-implement approach to assess non-additive effects that maybe extensible to other molecular systems in TPD and beyond.



Acknowledgements



Computational Molecular Design

Beste Özaydın

Jorge Duro



Xavier Barril

Carlos Modenutti

Marina Miñarro

Patricia Blanco

Arnau Comajuncosa

Marc Ciruela

Álvaro Serrano

Varbina Ivanova



Carles Galdeano

Alejandra Rodriguez

Elsa Martínez

Andrea Bertran

Roger Castaño

Ainoa Sánchez

Funding



This work was funded under the research projects PDI2020-115683GA-100 and RTI2018-096429-N-100 financed by the Ministry of Science and Innovation and the National Research Agency MCIN/AEI/10.13039/501100011033.

Computational facilities




RED ESPAÑOLA DE
SUPERCOMPUTACIÓN



**Barcelona
Supercomputing
Center**

Centro Nacional de Supercomputación

Understanding cooperative effects in PROTAC-Mediated Ternary Complexes for Protein Degradation



Computational
Molecular
Design
Lab



UNIVERSITAT DE
BARCELONA

Jordi Juarez-Jimenez, PhD

16th RES User Conference

14th September 2022